Affiliation:
1. N.N. Petrov National Medical Research Centre of Oncology; Saint-Petersburg Clinical and Practical Center of Specialized Types of Medical Care (oncological)
2. Saint-Petersburg Clinical and Practical Center of Specialized Types of Medical Care (oncological)
Abstract
Purpose: Percutaneous cryoablation (PCA) of renal cell carcinoma (RCC) stage T1a (≤4 cm) generally performed using MDCT with intravenous contrast material administration. Most interventional radiology departments are not equipped MDCT scanners and this is holding back widespread adoption of this technique into practical medicine. Flat-detector computed tomography (FDCT) is included in the standard equipment of modern angiographic systems, which makes it possible to combine the technologies of computed tomography with various technologies of intra-arterial contrasting and endovascular treatment. The purpose of the study was to assess the possibilities and potential advantages of using intraarterial contrasting during FDCT-controlled PCA of RCC T1a.Material and methods: Since 2017 angiographically assisted PCA under the FDCT control performed in 14 patients with RCC T1a. The procedure was performed in the X-ray operating room on an Artis Zee Floor angiographic unit with FDCT function and iGuide Needle Guidance and 3D/3D Fusion technologies (Siemens, Germany) using the SeedNet Gold system and IceEDGE 13 G, IceRod 17 G or IceSphere 17 G cryoprobes (Galil Medical, USA). At all stages of the procedure, FDCT-arteriography of the kidney (FDCT-A) performed according to the original technique: injection into the renal artery 12 ml of non-ionic contrast materials at a rate of 1 ml/s and performing scanning 5 s after the start of contrast materials injection.Results: The primary technical efficiency of FDCT-controlled PCA of RCC T1a was 92.9 %, the secondary — 100 %. Complications of grade 3 according to the CIRSE classification were identified in three patients (21.4 %), complications of grade 4, 5 and 6 not observed. The use of arterial access and the FDCT-A execution at different stages of PCA had the following advantages: 1) high-quality visualization of the tumor with minimal consumption of contrast materials; 2) simple and accurate positioning of cryoprobes using the iGuide Needle Guidance program; 3) estimation of the future ablative margin by fusion FDCT data about tumor with FDCT data about ice ball; 4) reliable diagnosis of bleeding after removal of cryoprobes with the possibility of immediate performing of endovascular hemostasis.Conclusion: Percutaneous angiographically assisted cryoablation under the FDCT control is an affordable, safe and effective technology for the treatment of RCC T1a, which has a number of potential advantages compared to performing procedures using MDCT control. Further research is advisable to study of this PCA technique with its subsequent possible introduction into the routine practice in Interventional Radiology departments of multidisciplinary oncological hospitals.
Publisher
Non-profit partnership Society of Interventional Oncoradiologists
Reference66 articles.
1. Krokidis ME, Orsi F, Katsanos K, et al. CIRSE Guidelines on Percutaneous Ablation of Small Renal Cell Carcinoma. Cardiovasc Intervent Radiol. 2017 Feb;40(2):177-91. DOI: 10.1007/s00270-016-1531-y.
2. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol. 2019 May;75(5):799-810. DOI: 10.1016/j.eururo.2019.02.011.
3. Campbell S, Uzzo RG, Allaf ME, et al. Renal Mass and Localized Renal Cancer: AUA Guideline. J Urol. 2017 Sep;198(3):520-9. DOI: 10.1016/j.juro.2017.04.100.
4. Klinicheskie rekomendatsii «Rak parenkhimy pochki». Nauchnyi sovet Ministerstva zdravookhraneniya Rossiiskoi Federatsii. 2021. Dostupno po: https://oncologyassociation.ru/wp-content/uploads/2021/02/rak-parenhimypochki-2021.pdf. [Clinical guidelines “Cancer of the renal parenchyma”. Scientific Council of the Ministry of Health of the Russian Federation. 2021. Available at: https://oncologyassociation.ru/wp-content/uploads/2021/02/rak-parenhimypochki-2021.pdf (In Russian)].
5. Escudier B, Porta C, Schmidinger M, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@ esmo.org. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 May 1;30(5):706-20. DOI: 10.1093/annonc/mdz056.